title: Canadian Adjuvant Initiative Workshop, March 26-27, 2013--Ottawa, Canada.
abstract: Novel adjuvants hold the promise for developing effective modern subunit vaccines capable of appropriately modulating the immune response against challenging diseases such as those caused by chronic and/or intracellular pathogens and cancer. Over the past decade there has been intensive research into discovering new adjuvants, however, their translation into routine clinical use is lagging. To stimulate discussion and identify opportunities for networking and collaboration among various stakeholders, a Canadian Adjuvant Initiative Workshop was held in Ottawa. Sponsored by the National Research Council Canada, Canadian Institutes of Health Research and the Vaccine Industry Committee, a two day workshop was held that brought together key Canadian and international stakeholders in adjuvant research from industry, academia and government. To discover innovation gaps and unmet needs, the presentations covered a board range of topics in adjuvant development; criteria for selection of lead adjuvant candidates from an industry perspective, discovery research across Canada, bioprocessing needs and challenges, veterinary vaccines, Canadian vaccine trial capabilities, the Canadian regulatory framework and WHO formulation laboratory experience. The workshop concluded with a discussion on the opportunity to create a Canadian Adjuvant Development Network. This report details the key discussion points and steps forward identified for facilitating adjuvant development research in Canada.
authors.affiliation: National Research Council-Human Health Therapeutics (NRC-HHT); Ottawa, ON Canada.
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Krishnan
authors.affiliation: National Research Council-Human Health Therapeutics (NRC-HHT); Ottawa, ON Canada.
authors.forename: Susan
authors.initials: S
authors.lastname: Twine
authors.affiliation: Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac); Saskatoon, SK Canada.
authors.forename: Volker
authors.initials: V
authors.lastname: Gerdts
authors.affiliation: National Research Council-Human Health Therapeutics (NRC-HHT); Ottawa, ON Canada.
authors.forename: Luis
authors.initials: L
authors.lastname: Barreto
authors.affiliation: National Research Council-Human Health Therapeutics (NRC-HHT); Ottawa, ON Canada.
authors.forename: James C
authors.initials: JC
authors.lastname: Richards
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000302:isolation & purification* / Q000494:pharmacology*; D002170:Canada; D002908:Chronic Disease / Q000628:therapy; D004493:Education; D006801:Humans; D007114:Immunization / Q000379:methods*; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000628:therapy; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D022223:Vaccines, Subunit
keywords: adjuvants; bioprocessing; regulatory approval; vaccine delivery systems; vaccines; veterinary vaccines